SkyePharma boosted by European progress for Flutiform and US Exparel launch
This article was originally published in Scrip
Executive Summary
SkyePharma has revealed that the Netherlands was the member state that had been unable to reach consensus with reference member state, the UK, regarding the company filing for the asthma treatment Flutiform (fluticasone propionate plus formoterol fumarate), under the decentralised procedure.